Sekwon Jang

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella et al. · Journal of Clinical Oncology · 2022 · 127 citations

Medicine, Oncology, Pharmacotherapy +17

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi et al. · Neuro-Oncology · 2021 · 125 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

Hussein Tawbi, Peter Forsyth, F. Stephen Hodi et al. · Journal of Clinical Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacotherapy +15

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Adi Diab, Scott S. Tykodi, Gregory A. Daniels et al. · Journal of Clinical Oncology · 2021 · 81 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

Charles W. Abbott, Sean M. Boyle, Rachel Marty Pyke et al. · Clinical Cancer Research · 2021 · 58 citations · Full text

Life Sciences, Immunology, Oncology +17